Philips and the U.S. government collaborate in ventilator production ramp up to combat COVID-19 pandemic
April 08 2020 - 12:45PM
Philips and the U.S. government collaborate in ventilator
production ramp up to combat COVID-19 pandemic
April 8, 2020
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced that the U.S. Government and Philips agreed to team up to
increase the production of hospital ventilators in its
manufacturing sites in the U.S. Philips plans to double the
production by May 2020 and achieve a four-fold increase
by the third quarter of 2020 for supply to the U.S. and global
markets. Such ventilators are critical for the treatment of
patients with the new coronavirus disease (COVID-19). Philips will
invest several tens of millions in its ventilator manufacturing
sites in the U.S.
“We are actively collaborating with the U.S. government to help
save lives in the U.S. and across the globe,” said Frans van
Houten, CEO of Royal Philips. “There is an unprecedented global
demand for medical equipment to help diagnose and treat patients
with COVID-19. We welcome the support of the U.S. government in our
efforts to aggressively increase the production of hospital
ventilators. We believe in fair allocation of scarce medical
equipment to those who need it the most, and we are ramping up to
deliver 43,000 units to the most critical regions in the U.S. in
the coming weeks and months through December 2020.”
In line with the recent call to action by the International
Chamber of Commerce (ICC) and World Health Organization (WHO),
Philips and the U.S. government have agreed to work together to
accelerate access to critical materials and components, expedite
logistics and regulatory approvals, in order to rapidly increase
the production of ventilators.
In the first three months of this year, Philips already
delivered several thousand ventilators to U.S. hospitals. As a
result of its production ramp up, Philips was able to deliver an
additional batch of ventilators to one of New York’s hospitals, to
help provide immediate relief to the surge of COVID-19 patients
within the city.
Philips believes that critical medical equipment, such as
hospital ventilators, should be made available across the world
using a fair and ethical approach to allocate supply to acute
patient demands based on data such as the COVID-19 statistics per
country/region (e.g. provided by the WHO and Johns Hopkins
Coronavirus Resource Center) and the available critical care
capacity. Philips may divide orders into batches to be delivered in
phases, so that the company can simultaneously serve multiple
countries/regions in need.
For further information, please contact:
Steve KlinkPhilips Global Press OfficeTel.: +31 6
10888824E-mail: steve.klink@philips.com
Leandro MazzoniPhilips Investor RelationsTel.: +31 20 59
77222E-mail: leandro.mazzoni@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips' health technology portfolio generated 2019
sales of EUR 19.5 billion and employs approximately 80,000
employees with sales and services in more than 100 countries. News
about Philips can be found at
http://www.philips.com/newscenter.
Forward-looking statements This release
contains certain forward-looking statements with respect to the
financial condition, results of operations and business of Philips
and certain of the plans and objectives of Philips with respect to
these items. Examples of forward-looking statements include
statements made about the strategy, estimates of sales growth,
future EBITA, future developments in Philips’ organic business and
the completion of acquisitions and divestments. By their nature,
these statements involve risk and uncertainty because they relate
to future events and circumstances and there are many factors that
could cause actual results and developments to differ materially
from those expressed or implied by these statements.
- Philips Trilogy in use hospital
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024